Phase I Study of the Combination of Bortezomib and Sorafenib Followed by Decitabine in Patients With Acute Myeloid Leukemia

Trial Profile

Phase I Study of the Combination of Bortezomib and Sorafenib Followed by Decitabine in Patients With Acute Myeloid Leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Bortezomib (Primary) ; Sorafenib (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 24 Dec 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov. .
    • 09 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2014 to 1 Dec 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top